Jane Street
KYTX icon

Jane Street’s Kyverna Therapeutics KYTX Stock Holding History

Jane Street’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-54,800
Closed -$515K – 13204
2025
Q4 		$515K Buy
+54,800
New +$407K ﹤0.01% 7615

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Jane Street's KYTX Position: Q1 2026 in Review

Jane Street reduced its Kyverna Therapeutics (KYTX) stake by 43% in Q1 2026, selling an estimated $649K and leaving 104,214 shares worth $899K. The position accounts for ﹤0.01% of the portfolio, ranked #6745.

Jane Street first reported a position in KYTX in Q1 2024 and has held it in 7 quarters since. The position peaked at $1.71M in Q4 2025. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • Jane Street held 104,214 shares of Kyverna Therapeutics worth $899K as of Q1 2026.
  • Jane Street sold 77,879 Kyverna Therapeutics shares in Q1 2026, an estimated $649K.
  • Kyverna Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #6745 holding.
  • Jane Street first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 7 quarters since.
  • Jane Street's Kyverna Therapeutics position peaked at $1.71M in Q4 2025.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.